Michael Caligiuri, a renowned physician-scientist is the President of City of Hope National Medical Center, and Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He directed The Ohio State University Comprehensive Cancer Center for 14 years prior as well as being the chief executive officer of The James Cancer Hospital and Solove Research Institute for 10 years. Caligiuri’s research focuses on the development and activation of human natural killer cells and their modulation for the treatment of leukemia, myeloma, and glioblastoma. He is a fellow and the immediate past president of the American Association for Cancer Research and has been elected to the National Academy of Medicine (NAM), one of the highest honors in the fields of health and medicine. Azra Raza, oncologist and researcher at Columbia University, author of The First Cell (October 2019 release), asks leading investigators the same five questions about the current cancer paradigm. Their variegated answers shed new light on why many new cancer treatments are failing and how to do better.
Questions:
1. We were treating AML with 7+3 in 1977. We are still doing the same. What is the best way forward to change it by 2028?
2. There are 3.5 million papers on cancer, 135,000 in 2017 alone. There is a staggering disconnect between great scientific insights and translation to improved therapy. What are we doing wrong?
3. The fact that children respond to the same treatment better than adults seems to suggest that the cancer biology is different and also that the host is different. Since most cancers increase with age, even having good therapy may not matter as the host is decrepit. Solution?
4. You have great knowledge and experience in the field. If you were given limitless resources to plan a cure for cancer, what will you do?
5. Offering patients with advanced stage non-curable cancer, palliative but toxic treatments is a service or disservice in the current therapeutic landscape?
0 Comments